These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35534835)

  • 1. Reliability analysis of exonic-breakpoint fusions identified by DNA sequencing for predicting the efficacy of targeted therapy in non-small cell lung cancer.
    Li W; Wan R; Guo L; Chang G; Jiang D; Meng L; Ying J
    BMC Med; 2022 May; 20(1):160. PubMed ID: 35534835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intergenic Breakpoints Identified by DNA Sequencing Confound Targetable Kinase Fusion Detection in NSCLC.
    Li W; Liu Y; Li W; Chen L; Ying J
    J Thorac Oncol; 2020 Jul; 15(7):1223-1231. PubMed ID: 32151779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
    Li W; Guo L; Liu Y; Dong L; Yang L; Chen L; Liu K; Shao Y; Ying J
    J Thorac Oncol; 2021 Mar; 16(3):404-418. PubMed ID: 33248323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers.
    Xia P; Zhang L; Li P; Liu E; Li W; Zhang J; Li H; Su X; Jiang G
    J Transl Med; 2021 Jul; 19(1):308. PubMed ID: 34271921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.
    Li W; Zhang J; Guo L; Chuai S; Shan L; Ying J
    J Thorac Oncol; 2017 Jan; 12(1):94-101. PubMed ID: 27614248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance.
    Vollbrecht C; Lenze D; Hummel M; Lehmann A; Moebs M; Frost N; Jurmeister P; Schweizer L; Kellner U; Dietel M; von Laffert M
    BMC Cancer; 2018 Nov; 18(1):1158. PubMed ID: 30466405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD74/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations.
    Li W; Fei K; Guo L; Wang Y; Shu C; Wang J; Ying J
    J Thorac Oncol; 2024 Apr; 19(4):613-625. PubMed ID: 38070598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective treatment in lung adenocarcinoma patient with brain metastases harboring novel CLHC1/RNT4 intergenic region- ALK fusion: A case report.
    Xia H; Liang B; Liu G; Qi Y; Luo N; Li M
    Medicine (Baltimore); 2022 Apr; 101(14):e29134. PubMed ID: 35446297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel ALK fusions using DNA/RNA sequencing in immunohistochemistry / RT-PCR discordant NSCLC patients.
    Wang B; Chen R; Wang C; Guo J; Yuan M; Chen H; Xia X; Zhong D
    Hum Pathol; 2021 Aug; 114():90-98. PubMed ID: 34019866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non-small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in situ hybridization.
    Diks J; Tang Z; Altan M; Anderson S; Chen H; Rashid A; Yang RK; Routbort MJ; Patel KP; Toruner GA; Medeiros LJ; Tang G; Luthra R; Roy-Chowdhuri S
    Cancer Cytopathol; 2024 Jan; 132(1):41-49. PubMed ID: 37747438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
    Lin C; Shi X; Yang S; Zhao J; He Q; Jin Y; Yu X
    Lung Cancer; 2019 May; 131():62-68. PubMed ID: 31027700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.
    Rosenbaum JN; Bloom R; Forys JT; Hiken J; Armstrong JR; Branson J; McNulty S; Velu PD; Pepin K; Abel H; Cottrell CE; Pfeifer JD; Kulkarni S; Govindan R; Konnick EQ; Lockwood CM; Duncavage EJ
    Mod Pathol; 2018 May; 31(5):791-808. PubMed ID: 29327716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
    Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
    Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences.
    Tabbò F; Muscarella LA; Gobbini E; Trombetta D; Castellana S; Rigutto A; Galetta D; Maiello E; Martelli O; Tiseo M; Scotti V; Ghilardi L; Gregorc V; Sergi C; Pilotto S; Del Conte A; Cappuzzo F; Cortinovis D; Osman G; Bareggi C; Di Maio M; Rossi A; Rossi G; Bria E; Volante M; Scagliotti GV; Graziano P; Novello S; Righi L
    Eur J Cancer; 2022 Oct; 174():200-211. PubMed ID: 36044814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization of genomic breakpoints of ALK rearrangements in non-small cell lung cancer.
    Wang Z; Han Y; Tao H; Xu M; Liu Z; Zhu J; Li W; Ma J; Liu Z; Wang W; Ma T
    Mol Oncol; 2023 May; 17(5):765-778. PubMed ID: 36423218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detecting anaplastic lymphoma kinase (ALK) gene rearrangements with next-generation sequencing remains a reliable approach in patients with non-small-cell lung cancer.
    Ding Y; Sun C; Su W; Miao C; He X; Wang JS; Zhang ZH
    Virchows Arch; 2022 Sep; 481(3):405-419. PubMed ID: 35624360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer.
    McLeer-Florin A; Duruisseaux M; Pinsolle J; Dubourd S; Mondet J; Phillips Houlbracq M; Magnat N; Fauré J; Chatagnon A; de Fraipont F; Giaj Levra M; Toffart AC; Ferretti G; Hainaut P; Brambilla E; Moro-Sibilot D; Lantuejoul S
    Lung Cancer; 2018 Feb; 116():15-24. PubMed ID: 29413046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLC.
    Kuang Y; Xu P; Wang J; Zheng Y; Sun X; Li Z; Gan R; Li H; Guo Y; Yao F; Zhu C; Ke Z; Tang K
    Mol Diagn Ther; 2021 Jul; 25(4):487-494. PubMed ID: 34133003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients.
    Cai C; Tang Y; Li Y; Chen Y; Tian P; Wang Y; Gong Y; Peng F; Zhang Y; Yu M; Wang K; Zhu J; Lu Y; Huang M
    Lung Cancer; 2021 Feb; 152():104-108. PubMed ID: 33444901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches.
    Vendrell JA; Taviaux S; Béganton B; Godreuil S; Audran P; Grand D; Clermont E; Serre I; Szablewski V; Coopman P; Mazières J; Costes V; Pujol JL; Brousset P; Rouquette I; Solassol J
    Sci Rep; 2017 Oct; 7(1):12510. PubMed ID: 28970558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.